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Abstract
Background: There is a large amount of gene expression data that exists in the public domain. This data has been
generated under a variety of experimental conditions. Unfortunately, these experimental variations have generally
prevented researchers from accurately comparing and combining this wealth of data, which still hides many novel
insights.
Results: In this paper we present a new method, which we refer to as indirect two-sided relative ranking, for
comparing gene expression profiles that is robust to variations in experimental conditions. This method extends
the current best approach, which is based on comparing the correlations of the up and down regulated genes, by
introducing a comparison based on the correlations in rankings across the entire database. Because our method is
robust to experimental variations, it allows a greater variety of gene expression data to be combined, which, as we
show, leads to richer scientific discoveries.
Conclusions: We demonstrate the benefit of our proposed indirect method on several datasets. We first evaluate
the ability of the indirect method to retrieve compounds with similar therapeutic effects across known
experimental barriers, namely vehicle and batch effects, on two independent datasets (one private and one public).
We show that our indirect method is able to significantly improve upon the previous state-of-the-art method with
a substantial improvement in recall at rank 10 of 97.03% and 49.44%, on each dataset, respectively. Next, we
demonstrate that our indirect method results in improved accuracy for classification in several additional datasets.
These datasets demonstrate the use of our indirect method for classifying cancer subtypes, predicting drug
sensitivity/resistance, and classifying (related) cell types. Even in the absence of a known (i.e., labeled) experimental
barrier, the improvement of the indirect method in each of these datasets is statistically significant.
Background
There is a large amount of gene expression data, gener-
ated from microarray experiments, that exists in the
public domain. Gene expression microarrays attempt to
measure the amount of mRNA that is transcribed. This
gives an estimate of the amount of protein that will be
translated from this mRNA. Proteins are responsible for
most of the work that is done in the cell, whether it is
breaking down compounds, signaling other cells or
pathways, or even making up the infrastructure and
m a c h i n e r yt oc o n t i n u et ot r a n s c r i b eD N Ai n t om R N A .
Traditionally, gene expression profiling has been used to
understand the underlying mechanism of biological pro-
cesses and pathways [1,2], to segment and explain dis-
eases and their subtypes [3,4], and to predict cancer
prognosis [5,6]. In addition, because it represents how
the cell responds to each compound, gene expression
data may be a good source for investigating whether
two drugs could have a similar therapeutic effect [7].
Unfortunately, gene expression data is inherently com-
plex and difficult to analyze and compare. First, there
are many factors that complicate the process including
post-transcriptional modification (e.g., splicing), degra-
dation of the mRNA, changes in the translation rates
from mRNA to polypeptide chains, as well as post-
translational modification (e.g., phosphorylation). Sec-
o n d ,t h ee x i s t i n gd a t ah a sb e e ng e n e r a t e db ym a n yd i f -
ferent laboratories across the world in a variety of
experiments. These experiments can be testing many
different hypotheses, such as the effect of a drug, i.e.,
which pathways and genes are affected by the drug, or
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experimental conditions are likely to result in confound-
ing effects on the gene expression profiles.
Historically, when researchers compare gene expres-
sion profiles, they limit themselves to data generated
under similar experimental conditions. Recently,
researchers at the Broad Institute developed a new
approach for detecting gene expression similarity.
Their tool, the Connectivity-Map (CMAP) [8],
addresses the problem of comparing gene expression
profiles generated under diverse experimental condi-
tions. Similar to Natsoulis et al. [7], the CMAP
approach relies on both positive (reward) and negative
(penalty) genes/probes. This builds on Golub et al. [3],
who demonstrated using a weighted voting scheme to
select gene lists in the context of classifying cancer.
Unlike these previous methods, Lamb et al. [8] use a
distribution statistic to compare the ranked lists of
expression probes. They show that this method is able
to overcome some of the experimental noise that can
affect the gene expression profile. This noise can be
from a wide range of confounding factors such as the
vehicle used to deliver the compound or the cell line
used for the experiment.
In this paper, we introduce a new similarity measure
for comparing ranked lists. Unlike the CMAP approach,
which performs a direct comparison of the gene expres-
sion profiles, our approach captures the correlations in
rankings between the target pair and the rest of the
database. This results in a method which is more robust
and is able to better cope with experimental barriers
such as vehicle and batch effects. We evaluate the ability
of this method for both retrieval and classification in
several datasets. Our contributions include:
￿ We formalize the problem of determining similar-
ity in gene expression data as a comparison of
ranked lists.
￿ We describe the CMAP approach, a direct
approach, to comparing ranked lists.
￿ We introduce our novel indirect approach to com-
paring ranked lists.
￿ We evaluate both methods on a two drug discov-
ery datasets, and show how our new method is able
to overcome experimental noise and obtain 97.03%
and 49.44% improvement in recall of similar drugs
over the direct approach.
￿ We further evaluate our method on three addi-
tional datasets and demonstrate the ability of our
indirect method to work in other gene expression
tasks, e.g., classifying cancer subtypes, predicting
drug sensitivity/resistance, and lastly classifying
(related) cell types.
Results
Problem Definition
Given a database D of treatments, i.e., drugs or other
compounds, D = t1, ..., tn, we are interest in querying
the database with a selected query treatment and return-
ing other similar treatments. Typically we know the
therapeutic use or indication for the query, but may not
have complete therapeutic information for all the entries
in the database. We are trying to discover other drugs
or treatments, perhaps originally developed for a differ-
ent therapeutic purpose, that are likely to also share the
same therapeutic properties as the query. These drugs
then are good candidates for further evaluation of a new
use.
More specifically, for each treatment instance t in the
database, there is both general information about
the experimental conditions of the sample, as well as the
actual experiment data from the microarray itself. The
microarray data consists of a collection of probe sets,
probes(t). Each probe p Î probes(t) measures the match
to a particular genomic sequence. For each probe p,
there is a raw expression value EV (p) (calculated using
MAS 5 algorithm [9]), as well as an amplitude A(p) (the
difference compared to control). The control is a refer-
ence baseline which is the average expression value cal-
culated from multiple untreated samples run within the
same vehicle and batch. Information specific to the treat-
ment, i.e., the name of the drug, the therapeutic class
(class) and subclass (subclass) as defined by the Physi-
cians Desktop Reference (PDR) is also represented. Addi-
tionally, there is information that describes the
experimental conditions of the sample, specifically the
molar amount of substance (mol), the vehicle used for
delivery of the drug (e.g., water, EtOH, MeOH, DMSO)
and the batch or round in which the sample was run.
We are interested in retrieving treatments t that are
similar in some way to a query treatment q. We mea-
sure similarity based on the probes of t and q.R a t h e r
than measuring the absolute similarity in expression
levels, we compare the ranking of the probes. Using the
ranks allows for a nonparametric comparison of the
gene expression profiles. Nonparametric methods have
been shown to work well for detecting differentially
expressed genes in microarray data [10-12]. As men-
tioned above, probes have both a raw expression value
and an amplitude. This ranking can be done based on
either the raw value or the amplitude. We utilize the
amplitude because it measures the treatment effect. We
use r(p, probes(t)) to denote the rank of p in probes(t); i.
e., if the probes are sorted in order of their amplitude,
then the rank is the position of p in that ordering. We
also introduce the uptags of t, Up(t) and the downtags
of t, Down(t). Up(t) is the set of k highest ranked probes
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control, and Down(t)i st h es e to fk lowest ranked
probes in probes(t), i.e., the most downexpressed as
compared to control. The parameter k is adjustable and
is defined by the user.
Comparing Rankings
We are interested in finding drugs with similar thera-
peutic effect by comparing the rankings of probes in
gene expression profiles of the drugs. The most straight-
forward approaches to compare these ranked lists, for
example calculating the intersection of Up(q)a n dUp(t),
quickly fail when there is any experimental noise. More
robust methods are needed to be able to combine and
draw conclusions from the large amount of gene expres-
sion data that has been created across the world.
A Two-sided Approach
A more sophisticated approach to comparing the simi-
larity of two rankings is to compare both the uptags and
downtags, and rather than looking simply at the overlap
in the sets of tags, take into account the relative ranking
of the probe. We will refer to this approach as the two-
sided relative ranking approach. This type of approach
m a yb ea b l et oc o r r e c t l yw e i g h tb o t he n d so ft h er a n k -
ing and overcome noise in the experimental data.
The CMAP approach [8] is a recently introduced
treatment retrieval method that is an example of a two-
sided relative ranking approach. Here we explain the
CMAP method and ground it in our example domain.
The following equations are adapted from Lamb et al.
([8]) and are based on their definition of gene set
enrichment [2]. The CMAP method is based on a simi-
larity measure which uses a truncated Kolmogrov-Smir-
nov (KS) [13] statistic applied to the up and down
probes of the treatments. The KS statistic measures the
similarity between two distributions; the truncated KS
statistic focuses on the taile n d so ft h ed i s t r i b u t i o n s .
Given a query treatment q and target treatment t,t h e
KS score is high if a) the probes in Up(q)t e n dt oa l s o
be highly ranked in t,b )t h ep r o b e si nDown(q)t e n dt o
have low ranks in t, and finally c) the probes in Up(q)
tend to be more highly ranked in t than the probes in
Down(q). This is similar to the truncated statistical
approach seen in [14] in the whole genome association
study in search of genetic markers for continuous traits.
The KS statistic of treatment instance t,g i v e naq u e r y
instance q, KS(t, q), is computed using the uptags and
downtags of q and the full ranking of all the probes in t.
KS(t, q), in turn, is computed from two separate statis-
tics, KSu(t, q)a n dKSd(t, q), which are calculated on the
uptags and downtags of q respectively.
KSu(t, q) measures where the uptags of the query are
located within the distributi o no fp r o b e si nat r e a t m e n t
instance t. It is a number between -1 and 1. If it is close
to 1, it tells us that the uptags of q are also highly
ranked in t, or more specifically that the probes that are
most upexpressed in the query instance also tend to be
upexpressed in the treatment instance.
In order to compute KSu, based on the selected set of
probes, Up(q), we define Upt(q) to be the probes in Up
(q) sorted according to their rank in t, r(p, probes(t)).
Next we define the rank of p in this new sorted set of
probes:
r p Up q p Up q tt (, () () .  the position of   in 
We introduce shorthand pt = r(p, probes(t)) and pq = r
(p, Upt(q))
Now we have the required information to compare the
probe distributions between the query and each treat-
ment. Let
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KSd is calculated analogously using Down(q). To com-
pute KSd, based on the selected set of probes, Down(q),
we define Downt(q)t ob et h ep r o b e si nDown(q)s o r t e d
according to their rank in t, r(p, probes(t)). Next we
define the rank of p in this new sorted set of probes:
r p Down q p Down q tt (, () ) () .  the position   in 
We assign pq = r(p, Downt(q)) and calculate a, b and
KSd as before.
Finally we can calculate the truncated KS statistic
using the KSu and KSd as follows:
KS t q
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Referring back to our original description of the prop-
erties that we were looking for in the KS statistic we see
that when the sign of KSu and KSd are the same,
whether both positive or both negative, then the KS
score is set to zero. This indicates that there is a signifi-
cant overlap between the two distributions. No clear
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domly dispersed, and that this ranked list is not statisti-
cally similar to the query sequence. In the case where
the sign of the two values is different then the final KS
score represents the separation between the two distri-
butions. This is done by calculating the difference
between KSu and KSd.
The CMAP approach was developed as a query system
that directly compares the query to each treatment in
the database. It does not take into account any further
information about how the treatment instances in the
database relate to each other. We refer to this as a direct
approach.
Indirect Two-sided Approach
Next, we introduce an indirect two-sided relative rank-
ing method which compares the similarity between the
query and treatment instance by comparing their corre-
sponding similarity to all the instances in the database.
Ideally, by combining hundreds, thousands, or even mil-
lions of pairwise distances, a more robust similarity
measure can be obtained. This is similar in spirit to a
vantage point method for computing similarity in metric
spaces, where the distance between a pair of points is
computed based on their distance to a collection of van-
tage points [15]. An illustration of the difference
between our indirect method and a simple direct simi-
larity method is shown in Figure 1.
Our indirect two-sided relative ranking is calculated
by comparing the correlation between how two treat-
ments compare to the rest of the database. There are
many correlation measures, including parametric statis-
tics such as Pearson coefficient and nonparametric sta-
tistics such as Spearman rank correlation coefficient.
Since we do not know ahead of time if the gene expres-
sion data is normally distributed, it is safer to use a
nonparametric correlation measure. We use the Spear-
man rank correlation coefficient.
We compute the Spearman rank correlation coeffi-
cient by measuring the difference between the KS statis-
tics for the query q and target treatment t,f o ra l lt h e
treatments in the database D. Let KSD(q)={ KS(q, t1),
KS(q, t2), ..., KS(q, tn)} and let KSD(t)={ KS(t, t1), KS(t,
t2), ..., KS(t, tn)}. Then we define the indirect two-sided
relative ranking of a query q and a treatment t, I2R(t, q)
to be:
IR tq S p e a r m a n K S qK S t DD 2( ,) ( () , ( ) ) 
where Spearman is the Spearman correlation statistic,
which we will formally define next.
Let r(KS(q, ti), KSD(q) )b et h er a n ko ft h es c o r eo f
instance ti (KS(q, ti)) out of all scores returned (KSD(q))
when querying with q and analogously let r(KS(t, ti),
KSD(t)) be the rank of the score of instance ti out of all
scores returned when querying with t.
1
6 2
1
2 1

  

rK Sqt i KSD qr K S t t i KSD t i
n
nn
(( , ) , ( ) )(( , ) , ( ) )
()
where n is the number of instances in the database.
This score is calculated using the ranks of all of the
pairwise KS scores from q and t to each other instance
ti. This is equivalent to taking the Pearson’s correlation
over the ranks. In the case where there are tied ranks,
the full Pearson’s correlation over ranks must be calcu-
lated. The indirect similarity score is therefore a calcula-
tion of how two instances individually compare to the
full database (inclusive of the query and target). If they
tend to be similar, or dissimilar, to the same instances,
then they are more likely to be similar to each other.
Figure 1 Direct vs. Indirect Similarity. (a) The direct similarity method evaluates a given pair of instances without taking into account any
other knowledge in the database. (b) The indirect similarity method benefits from the extra knowledge within the database, comparing the
similarity of the pair to all the instances in the database and uses this information to determine the similarity between a given pair of instances.
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any individual pairwise similarity available. Here we
have taken what we believe to be the current best
method, the KS statistic from the CMAP approach, and
used this as our source of pairwise similarities. If other
direct similarity measures for this domain become avail-
able, we can easily incorporate them. Another advantage
of this method is that as more treatments are added to
the database, additional evidence is available, which can
further increase the accuracy of our indirect similarity
calculation.
Discussion
As mentioned at the outset, one of the tasks that we
are interested in is finding similar treatments by com-
paring the gene expression profiles of drugs. Specifi-
cally, our goal is to improve the ability to detect
similarity in the presence of experimental noise. We
focus our evaluation on the case where we have known
experimental noise, e.g., when 1) the samples come
from different vehicles, 2) they belong to different
batches, or 3) they differ in both vehicle and batch
(which corresponds to the most labeled experimental
noise). Though vehicle and batch are not the only
sources of experimental noise, they can easily be evalu-
ated as they are both annotated.
The ideal outcome of such a discovery program is the
in vivo validation of a drug predicted by gene expression
similarity to be useful for an unknown, alternative indi-
cation. To simulate this goal, we propose calculating the
recall at rank k of drugs of the same PDR classification.
More specifically, we query the database with each drug
from a particular indication and we measure the total
number of drugs recalled across the top k results from
all of the individual queries. We measure this recall of
drugs which are known to be used for the same indica-
tion across vehicles, across batches, and across both
vehicles and batches. We focus our analysis on the most
populated PDR classifications, where 10 or more drugs
from each group have been profiled, which results in 14
different groups. This filtering of groups is done to
avoid unrepresentative results caused by a small sample
size. For the evaluation we select recall at rank k = 10,
but we also demonstrate that these results are not
greatly affected by variations in k.
Sample Evaluation
Given the group Histamine Antagonists, we calculate the
recall at rank 10 as follows:
1. For each histamine antagonist, determine the 10
most similar compounds using each method (direct
vs indirect).
2. Count the number of compounds of the same
class, i.e., Histamine Antagonist, that are screened in
a different vehicle and different batch.
3. Improvement of indirect over direct is represented
as:
([ ] [ ]) /[ ] indirect direct direct 
where [indirect] and [direct] are the number of
recalled treatments from the top 10 of each method
respectively.
4. When [direct] = 0, and [indirect] ≥ 0t h e nw e
make note of this improvement as a special case.
Reporting percent improvement does not make
sense when the baseline is 0, so we do not include
these in our overall improvement calculation, but we
note them as they are very important special cases
where the existing approach returns nothing, while
our approach returns useful results.
The results of our example of comparing the two
similarity methods for recall at rank 10 across both dif-
ferent vehicles and different batches for the Histamine
Antagonists are shown in Table 1. It is important to
note that these are the total number of drugs recalled
across all of the histamine antagonists used to indepen-
dently query the database. In this case, the direct
method finds two results while indirect finds three,
which is an improvement of 50%. This example analysis
compares the ability to recall other histamine antago-
nists across both vehicles and batches.
Using the evaluation criteria presented above, we
compare the ability of the two methods (direct and
indirect) to overcome experimental noise. We evaluate
how these methods work on two different datasets
within the drug discovery domain. The first is a large,
proprietary dataset (GEPedia) from Vanda Pharmaceuti-
cals. This dataset contains a large number of drugs that
have been profiled. While this dataset is not currently in
the public domain we feel that it is worth describing
these results as they demonstrate that this method is in
fact being employed in a real world drug discovery
engine. Realizing that this analysis provides only anecdo-
tal evidence of this method, we therefore also include an
Table 1 Example evaluation comparing the direct and
indirect methods.
Number of results returned by direct 2
Number of results returned by indirect 3
Improvement of indirect over direct 50%
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Institute http://www.broad.mit.edu/cmap which contains
453 profiles. It is important to note that this dataset
includes a substantial amount of replicates for many of
the compounds.
Vanda GEPedia Summary Results
We start by comparing the two methods, direct and
indirect, using the Vanda GEPedia dataset. Once again,
these results are being provided as anecdotal evidence of
how this method performs in a real drug discovery
engine. The average recall at rank 10 for the 14 PDR
groups is presented in Table 2. The indirect method
improves over the direct method and is able to recall
71.44% more true positives when searching across differ-
ent vehicles. The positive predictive value (PPV)
increases from 2.0% for the direct method to 2.3% for
the indirect method. The PPV is calculated for each
group independently; we present the average PPV across
all of the groups. The improvement in recall of known
similar drugs is increased when searching across batches
to 94.93% (Direct PPV of 2.1% vs. Indirect PPV of
2.7%). When attempting to detect similarity across both
vehicles and batches, which represents the most experi-
mental noise in our setup, the indirect method has an
improvement in recall of 97.03% as compared to the
direct method (Direct PPV of 1.3% vs. Indirect PPV of
1.7%). While the PPV appears low for both methods, it
is important to realize that the expected discovery rate
o fad r u ge n g i n ei si n h e r e n t l yl o w ,a n dt h a to u re v a l u a -
tion method only considers already labeled true posi-
tives. Additionally, other steps could be taken to
determine which candidates to move forward including
for example, obtaining further evidence from literature,
desired characteristics for the particular indication (e.g.,
the ability to cross the blood-brain barrier), or conduct-
ing in vitro experiments. The indirect similarity method
recalls almost twice the amount of true positives (similar
drugs) as the direct method. This level of improvement
brings the potential for important scientific discovery
and impact of such a system.
As mentioned earlier, the average percentage improve-
ment does not capture the important special case that
occurs if one of the methods does not retrieve any treat-
ments. These special cases are further examples of the
ability of the indirect similarity method to detect simi-
larity when the direct method cannot. These cases are
listed below for those found across different vehicles,
across different batches, and lastly across both different
vehicles and different batches (Table 3).
We have shown how overall, the indirect method
which uses the Spearman rank correlation has a higher
recall at rank 10 than the direct KS method.
Vanda GEPedia In Depth Analysis
Next we study the three largest groups (the groups with
the most compounds profiled) in more detail: Antibiotic,
Histamine Antagonist, and Analgesic, in order to a)
further inspect the differences in the results returned by
each of the methods and b) to verify that this is not an
artifact of using k = 10.
Antibiotic
The Antibiotic group has the largest amount of com-
pounds in the database (n = 58). This group is in the
PDR class Anti-Infective and the PDR subclass Antibio-
tic. An antibiotic drug is one that inhibits the growth of
micro-organisms. The indirect method is able to recall
eight antibiotics when searching across both vehicle and
batch, compared to 0 recalled by the direct method.
This result is not driven by any single treatment, i.e.,
each of these 8 recalled treatments is not only unique,
but they are also recalled by distinct query treatments.
Next, we demonstrate that these results are not biased
by our selection of k = 10. Figure 2(a) shows the recall
of the two methods across both different vehicles and
batches with values of k ranging from 10 to 100. The
indirect method is able to recall more true positives
independent of k. We can also evaluate how the meth-
ods compare when searching over vehicle or batch sepa-
rately. Figure 2(b) shows that when searching across
different vehicles only, the same trend is seen as in Fig-
ure 2(a). Similarly, evaluating the two methods when
searching across different batches (Figure 2(c)), a similar
trend is seen in which the indirect method outperforms
the direct method regardless of k.
Histamine Antagonist
The Histamine Antagonist group contains the second
largest number of compounds profiled (n =2 4 ) .T h i s
group is made up of drugs in the PDR class Respiratory
Agent and PDR subclass Histamine Antagonist. A hista-
mine antagonist inhibits the release or minimizes the
action of histamine. There are several subtypes of
Table 2 Percent improvement of indirect similarity recall
over direct similarity recall in different conditions.
Across Different Vehicles 71.44%
Across Different Batches 94.93%
Across Different Vehicles & Batches 97.03%
Table 3 Instances found in conditions where the direct
method had found none.
PDR Class Vehicle Batch Vehicle + Batch
Antibiotic 12 11 8
Anesthetic 1 1 1
Antihypertensive 1 1 0
Anticonvulsant 0 2 2
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batches. There are n = 56 Antibiotic instances in this dataset.
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the different histamine receptors. The H1 receptor
antagonists, sometimes referred to as antihistamines, are
clinically used to treat allergies. The other common sub-
type, the H2 receptor antagonist, are commonly used to
control the secretion of gastric acid. There are other
subtypes, namely H3 and H4, however, they are not
often used clinically. Once again we do not distinguish
between these subtypes for our analysis; we use the PDR
classification.
As discussed earlier, for the histamine antagonists,
the direct method is able to recall two antihistamines
at or below rank 10 while the indirect method is able
to recall three. This corresponds to an increase of 50%.
More specifically, the indirect method recalls the same
two treatments as the direct method in addition to a
third novel treatment. Figure 3(a) shows the ability of
each method to recall histamine antagonists across
both different vehicles and batches. The recall at rank
2 0a n da tr a n k3 0i st h es a m ef o rt h et w om e t h o d s ,
and then as k increases the indirect method improves
in its ability to recall histamine antagonists as com-
pared to the direct method. In splitting up the vehicle
(Figure 3(b)) and batch (Figure 3(c)) analysis, we see
that the direct method is outperforming the indirect
method in the across vehicle analysis for smaller k,
while underperforming against the indirect method in
the across batch analysis, which contains more
instances.
Analgesic
The last group that we individually analyze is the
Analgesic group (n = 23). This group is defined as drugs
belonging to the PDR class Central Nervous System
Agent and PDR subclass Analgesic. An analgesic, more
commonly known as a painkiller, acts in various ways
on the peripheral and central nervous system in order
to reduce pain. Searching across both vehicles and
batches the direct method is able to recall one analgesic.
The indirect method recalls the same treatment in addi-
tion to two other treatments. The indirect method is
able to recall three analgesics in total which corresponds
to a 200% percent increase in recall.
Figure 4(a) shows that the indirect method has a
higher recall rate at every level of k when searching
across both vehicle and batch. The same is true when
searching across just a different batch (see Figure 4
(c)). We see in Figure 4(b) that the indirect method
also does better for low k across different vehicles. It
is more important for a method to do better for low
k because in a drug discovery system you will start
validation on the most promising hits first. It quickly
becomes cost prohibitive to explore a large set of
leads.
Broad Dataset
Next, we replicate our findings using the publicly avail-
a b l eg e n ee x p r e s s i o nd a t a s e tf r o mt h eB r o a dI n s t i t u t e .
This dataset consists of 453 samples and was released
with the Connectivity Map tool. To allow for easier
reproducibility, we make use of the annotations pro-
vided on the CMAP website as opposed to custom
matching to the PDR annotations. In terms of PDR indi-
cations we instead use what is described as Therapeutic
Uses in the ChemBank [16] record linked to each
CMAP instance. There is no information provided
about the vehicles used for each sample. However, each
instance is associated with a batch, and so we will use
this information to segment our data. To remain consis-
tent and in order to have more confidence in the results,
only groups (Therapeutic Uses) with 10 or more
instances are used. The groups, along with the number
of instances in each group, are listed in Table 4.
Similar to what was observed before, the indirect simi-
larity measure recalls more compounds of the same
class than using the direct similarity measure alone. The
improvement of the indirect method over the direct
method is 49.44% on the Broad dataset. The average
PPV of the direct method is 6.2% compared to 7.6% for
the indirect method. Once again, the indirect method
allows for the ability to recall more true positives, and
the improvement is substantial.
We now analyze the three largest therapeutic groups
from the Broad dataset. Note that for this set of data we
explore a smaller size for k. Given that this is a smaller
database, we want to guarantee that we are only evaluat-
ing the top pairs. We begin our analysis with the Anti-
Inflammatory group.
Anti-Inflammatory
To illustrate this improvement, let us look at the group
with the most compounds: the anti-inflammatory group.
An anti-inflammatory drug is a substance that reduces
inflammation. Many analgesics are anti-inflammatory
agents, alleviating pain by reducing inflammation. The
direct approach is able to recall 16 compounds labeled
as anti-inflammatory that have been profiled in a differ-
ent batch (k = 10). The indirect approach, however, is
able to recall 28 compounds that also are classified with
a therapeutic use of anti-inflammatory. The improve-
ment of the indirect method over the direct method can
be seen in Figure 5(a). We see that the indirect method
is always better than the direct method, and this
improvement is even more pronounced with lower k
values.
Anti-Convulsant
The second group that we will focus on in the Broad
validation dataset is the anti-convulsant group. Anti-
convulsant drugs are used in the prevention and
Licamele and Getoor BMC Bioinformatics 2010, 11:137
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Page 8 of 19Figure 3 Histamine Antagonists Recall. Histamine Antagonist recall at rank k across (a) both different vehicles and batches, (b) different
vehicles, and (c) different batches. There are n = 24 Histamine Antagonist instances in this dataset.
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Page 9 of 19Figure 4 Analgesic Recall. Analgesic recall at rank k across (a) both different vehicles and batches, (b) different vehicles, and (c) different
batches. There are n = 23 Analgesic instances in this dataset.
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Page 10 of 19treatment of epileptic shock. The mechanism by which
these drugs work is by suppressing the rapid firing of
neurons. At k = 10 the direct method has a recall of 17
while the indirect method is able to recall 20 other anti-
convulsants (from different batches). Figure 5(b) shows
that this trend generally holds for this group, with a
slight dip at k = 20.
Anti-Psychotic
The last group that we will evaluate is the anti-psychotic
group, which has the third highest number of instances
in the Broad dataset. Anti-psychotic drugs are used to
treat psychosis. Neither method in this group is able to
recall as many instances as in the previous two groups.
The direct method recalls 9 anti-psychotics while the
indirect method recalls 6 (k = 10). The indirect method
is able to gain an advantage at k =3 0 ,h o w e v e r ,t h e n
the methods switch back again (Figure 5(c)). The recall
of both methods is much lower for this anti-psychotic
group (in the Broad dataset) than previous groups and
this is a possible explanation for why we do not see
improvement.
Evaluating the Statistical Significance of Improvement
We have demonstrated that our indirect method results
in a large improvement in the recall of similar com-
pounds over the direct method in the face of vehicle
and batch effects. Specifically, we have shown an
improvement of known true positives at rank 10 across
a number of therapeutic groups. We evaluate if the dif-
ference in ranks of these true positives is statistically sig-
nificant. Our indirect method does statistically better
than the direct (CMAP) approach in 33% of the groups
while remaining as accurate as the direct method on the
remaining groups. This analysis is performed for the
groups listed in Table 4 as follows. For each set of
instances belonging to a particular therapeutic group we
use both methods (direct and indirect) to determine the
top 100 similar instances per method. We avoid cases
where neither method recalls the true positives within
the top 100 instances, as differences this far down the
result listing is of limited practical interest. However, if
one method recalls an instance within the top 100, we
include the rank for the other method even if it is out-
side of the top 100, because we want to give either
method credit for these cases. We perform a paired
t-test between the two methods for each of the thera-
peutic groups. The indirect method is statistically better
in 3/9 of the therapeutic groups when evaluating the
top 100 results and is statistically equivalent (no statisti-
cal difference between the methods) in the other 6
groups. In selecting 100 as the threshold we evaluate at
several other thresholds as well. The indirect method is
never statistically worse than the direct method across
all 900 evaluations (9 groups × 10 rank thresholds) and
is statistically better in 22 cases, including being statisti-
cally better at all thresholds 20-100 for the anti-inflam-
matory group, which is the biggest group with 28
instances. The results for this analysis at a search
threshold of 100 are show in Table 5 and the followup
sensitivity analysis is shown in Table 6.
Evaluation For Classification on Additional Datasets
We have demonstrated how this novel method can work
in a large, gene expression based, drug discovery frame-
work which has been our motivating problem and focus.
We now analyze our indirect method on three smaller
(public) datasets. We evaluate how our indirect method
performs in distinguishing cancer types (acute myeloid
leukemia versus acute lymphoblastic leukemia) and in
predicting drug sensitivity/resistance. Additionally, we
demonstrate the ability to use our indirect method to
distinguish three very similar and related cell types in a
third dataset.
Molecular Classification of Cancer
Golub et al. [3] evaluated the use of gene expression sig-
natures to classify acute leukemias. They created a data-
base of expression profiles of both acute myeloid
leukemia (AML) and acute lymphoblastic leukemia
(ALL) samples and demonstrated how gene signatures
can help to classify these subtypes of acute leukemia.
This is an important task, as the appropriate treatment
for an individual depends on understanding the tumor
type. Maximizing efficacy and minimizing adverse events
and toxicity is the goal, and this is best achieved by pre-
scribing chemotherapies that target the correct patho-
genetically distinct tumor types.
This dataset consists of 52 samples (24 ALL and 28
AML). Analogous to searching for similar drugs we can
search for samples of the same cancer class, e.g., search-
ing with an ALL sample should yield other ALL sam-
ples. In order to perform the classification we use the
majority vote of the top k results. In this case, the
majority vote of the top 11 results (as opposed to 10 to
avoid ties) recalled by a given sample is used to classify
Table 4 Description of therapeutic groups within the
Broad Dataset.
Therapeutic Use Number of instances
anti-inflammatory 28
anti-convulsant 21
anti-psychotic (neuroleptic) 19
anti-proliferative 16
tranquilizer 16
anti-neoplastic 15
analgesic 13
immunosuppressive agent 13
cardiovascular agent 10
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Page 11 of 19Figure 5 Broad Validation Recall. Broad validation results with varying k on top 3 groups: (a) Anti-Inflammatory (n = 28) (b) Anti-Convulsant (n
= 21), and (c) Anti-Psychotic (n = 19).
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Page 12 of 19the sample. In this example, the direct method does
extremely well, accurately classifying every sample cor-
rectly. The indirect method also correctly classifies every
sample correctly. However, this is a high level compari-
son and we can understand and evaluate the results in
more detail by looking at the individual rankings upon
which the voting relies.
We describe the average rank (of samples of the same
class) across the two methods. The average rank for
ALL by the indirect method is 12.2 compared to 14.5
for the direct method. The AML class also demonstrates
an improvement where the average rank for the indirect
method is 20.5 versus 21.6 for the direct method. While
this improvement is consistent across both groups, the
small number of groups in this dataset does not readily
allow us to evaluate the statistical significance. For this
we instead evaluate the underlying ranks for each sam-
ple. The full results are listed in Table 7 and Figure 6
shows the corresponding ROC curve. The AUC for the
0.829 for the indirect method and 0.727 for the direct
method. This difference is statistically significant using
the method described by DeLong et al [17] (p = 1.13e-
32). Note that k is set to 250 to compensate for there
being roughly half of the probes as used in the previous
datasets (12, 564). The average rank improvement of
recalling similar samples is 1.7 when using the indirect
method as compared to the direct method.
Predicting Drug Sensitivity/Resistance
The next dataset (from Wei et al. [18]) that we evaluate
consists of ALL expression profiles of individuals that
are known to be sensitive or resistant to glucocorticoid
treatment, specifically in regards to childhood ALL. This
is an important task because a poor prognosis is linked
to resistance to glucocorticoid-induced apoptosis of pri-
mary lymphoblastic leukemia cells in vitro [19-22].
There are 13 glucocorticoid sensitive samples and 16
that are glucocorticoid resistant (total n = 29). As
b e f o r e ,w eu s eap a i r e dt - t e s tc o m p a r i n gt h ea v e r a g e
rank of recalling samples from the same class (i.e., sensi-
tive or resistant). The indirect method improves upon
the direct method by 0.45 on average across all samples.
There are 22, 283 probes used in this dataset and k is
set to 500. The full results are listed in Table 8 and the
ROC curve is shown in Figure 7. The AUC is 0.635 for
the indirect method and 0.608 for the direct method
(p = 1.90e-06).
Classifying (Related) Cell Types
The final dataset that we use to evaluate our indirect
method is from Lu et al. [23]. It consists of megakaryo-
cyte-erythrocyte progenitors (MEP) as well as the two
cell types that MEPs can differentiate into, namely
megakaryocytes and erythrocytes. Megakaryocytes are
bone marrow cells that are responsible for the produc-
tion of platelets while erythrocytes are red blood cells.
We refer to this dataset as the MEP dataset. The origi-
nal focus of Lu et al. [23] was to better understand the
differentiation process and was not evaluating the classi-
fication of these three cell types. There are 320 probes,
Table 5 Statistical Analysis of the Improvement in Rank
Therapeutic Use N Mean
Improvement
StdDev tValue P
analgesic 29 90.43 117.55 4.14 0.0003
anti-inflammatory 160 30.12 115.04 3.31 0.0011
anti-psychotic
(neurole)
69 25.57 73.36 2.90 0.0051
immunosuppressive
agent
67 7.96 40.42 1.61 0.1120
tranquilizer 68 14.43 73.95 1.61 0.1124
cardiovascular agent 22 10.82 69.37 0.73 0.4726
anti-neoplastic 54 10.33 114.65 0.66 0.5106
anti-convulsant 144 -4.50 92.09 -0.59 0.5585
anti-proliferative 86 -1.86 77.86 -0.22 0.8252
A paired t-test was performed to analyze the difference in the rank of true
positives returned by the direct and indirect method. N is the number of true
positives found within the top 100 results across the whole therapeutic group.
Improvement is the average improvement (rank direct - rank indirect).
Table 6 Statistical Analysis of the Improvement in Rank
Search Size: 10 20 30 40 50 60 70 80 90
Therapuetic Use
analgesic 0.136 0.087 0.041 0.020 0.001 2.0E-04 0.004 0.001 0.002
anti-convulsant 0.811 0.529 0.932 0.636 0.918 0.856 0.478 0.481 0.512
anti-inflammatory 0.151 0.040 0.034 0.033 0.002 0.001 0.003 0.002 0.004
anti-neoplastic 0.412 0.842 0.943 0.928 0.577 0.804 0.919 0.909 0.779
anti-proliferative 0.148 0.553 0.778 0.659 0.987 0.881 0.942 0.837 0.837
anti-psychotic (neurole 0.905 0.852 0.686 0.674 0.529 0.129 0.063 0.024 0.006
cardiovascular agent 0.647 0.267 0.496 0.496 0.540 0.795 0.984 0.801 0.687
immunosuppressive agent 0.047 0.664 0.642 0.550 0.525 0.525 0.554 0.323 0.323
tranquilizer 1.000 0.580 0.579 0.921 0.665 0.619 0.413 0.290 0.159
A sensitivity analysis using multiple paired t-tests was performed to analyze the difference in the rank of true positives returned by the direct and indirect
method at different search thresholds for rank k. Each cell contains the respective probability. All significant (P < .05) findings are confirmed to be in favor of the
indirect method.
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ratio as before.
This is another example of how the indirect method
can improve over the direct method even with a small
dataset. There are only 3 classes and 27 total samples of
which 9 are erythrocytes, 10 are megakaryocytes and 8
are MEPs. Analyzing the results in the same fashion as
before we find that the indirect method statistically
improves upon the direct method once again with an
average improvement of 1.1. The ROC curve is shown
in Figure 8 with the full listing of results in Table 9.
The AUC for the indirect method is 0.670 compared
with 0.633 for the direct method (p = 4.13e-13).
Computational Complexity
We have presented a comparison of our novel indirect
similarity method to the normal direct similarity method
in terms of increased true positives recalled at a given
threshold. We have thus far ignored the practical chal-
lenges that may occur in implementing either of these
methods in a production system. The transition to using
an indirect method has implications on both the time
needed for calculating the similarity, as well as the space
needed to store the information required by the system
to work efficiently.
One important thing to note is that we are evaluating
the difference between the indirect and direct similarity
methods in the context of a knowledge discovery frame-
work. In this situation, the system already performs all
pairwise similarity comparisons to detect novel insights.
This is quite different than the initial goal of the CMAP
method, which was first developed as a real-time, query
based tool for the web. The actual running time for the
direct analysis was ~24 hours to calculate the KS scores
versus ~3.6 hours for the indirect similarity calculation.
A fair amount of effort was spent optimizing the indir-
ect calculation and the indirect calculation additionally
benefited from being run on a highly parallel SAS server
optimized for such statistical calculations. We feel that
it is more important to evaluate the theoretical compu-
tational complexity which follows below. Additionally,
this theoretical analysis applies to any new direct
method.
Time Complexity
We assume that all the data has been preprocessed and
is stored as a rank-ordered list, reflecting the difference
Table 7 AML vs ALL Average Rank
Sample Class Indirect Direct
ALL 1 ALL 12.0 13.3
ALL 2 ALL 12.0 14.1
ALL 3 ALL 12.1 19.2
ALL 4 ALL 12.0 14.3
ALL 5 ALL 12.0 15.4
ALL 6 ALL 12.0 12.7
ALL 7 ALL 12.0 12.1
ALL 8 ALL 12.0 16.0
ALL 9 ALL 12.0 12.3
ALL 10 ALL 12.0 12.3
ALL 11 ALL 12.0 14.1
ALL 12 ALL 12.0 12.0
ALL 13 ALL 12.2 16.4
ALL 14 ALL 12.0 13.0
ALL 15 ALL 12.0 13.0
ALL 16 ALL 12.0 16.9
ALL 17 ALL 12.1 14.8
ALL 18 ALL 12.0 13.1
ALL 19 ALL 12.0 14.1
ALL 20 ALL 17.0 21.3
ALL 21 ALL 12.0 13.5
ALL 22 ALL 12.0 13.3
ALL 23 ALL 12.0 14.1
ALL 24 ALL 12.0 17.4
AML 1 AML 18.5 20.7
AML 2 AML 18.3 19.5
AML 3 AML 18.3 19.9
AML 4 AML 18.3 19.2
AML 5 AML 18.6 21.7
AML 6 AML 18.4 20.3
AML 7 AML 18.3 19.3
AML 8 AML 18.4 20.7
AML 9 AML 18.3 19.6
AML 10 AML 18.4 21.4
AML 11 AML 20.4 25.9
AML 12 AML 18.3 19.7
AML 13 AML 18.4 20.7
AML 14 AML 18.2 19.1
AML 15 AML 18.5 20.8
AML 16 AML 18.2 19.4
AML 17 AML 18.5 20.7
AML 18 AML 18.4 20.3
AML 19 AML 18.2 19.9
AML 20 AML 18.3 19.9
AML 21 AML 18.3 19.8
AML 22 AML 18.4 20.3
AML 23 AML 18.3 19.6
AML 24 AML 34.3 28.1
AML 25 AML 34.3 28.5
AML 26 AML 33.9 28.3
Table 7: AML vs ALL Average Rank (Continued)
AML 27 AML 34.3 30.4
AML 28 AML 14.0 22.4
The average rank of samples of the same class is listed for each sample. (ALL =
acute lymphoblastic leukemia; AML = acute myeloid leukemia)
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we are interested in the relative complexity of our indir-
ect method as compared to the complexity of the under-
lying direct method. As our indirect method can use any
underlying direct method as its base, we focus on the
relative complexity for a general comparison. Let us
assume that the computational cost of one individual
pairwise comparison using a given direct method is c1.
T h ec o m p l e x i t yo fp e r f o r m i n g all pairwise comparisons
using the direct method is shown in Eq. (3).
Tn
cn n
On ()
()
() 

 1 1
2
2 (3)
The implementation of the indirect method similarity
takes advantage of reusing this full matrix of direct
comparisons and does not naively recalculate any direct
similarities. Once again, assuming a small constant, c2,
to calculate the Spearman correlation for a given pair,
the time complexity of our indirect similarity method is
given in Eq. (4). It should be noted that in our current
experimental setup c2 <c1, as the computational com-
plexity of the KS statistic far outweighs the complexity
of the Spearman correlation.
Tn
cnn cnn
On ()
() ()
() 



 1 1
2
2 1
2
2 (4)
We have managed to keep the time complexity of our
indirect similarity method in the same order of magni-
tude as what is required by the underlying direct simi-
larity method. We next determine the impact that we
have on the space complexity of moving to an indirect
approach.
Space Complexity
The data that needs to be stored is that of the individual
ranked lists representing the treatments as compared to
their respective control. For our given application, this
works out to be m·n, where m is the size of each ranked
list (in our case 22, 283) and n is the number of treat-
ment instances. We ignore the negligible space require-
ment needed for one individual direct comparison since
this intermediary is not retained. The space complexity
is then once again O(n
2) and the direct similarities are
stored as a n × n matrix. Analogously, the indirect simi-
larities are also maintained in an n × n matrix requiring
O(n
2) space as well. In the current implementation, both
of these space requirements are overshadowed by the
large space requirements of the initial dataset itself.
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Figure 6 AML versus ALL ROC. ROC curve showing the difference in sensitivity and specificity between the direct and indirect method for the
task of predicting subtypes of cancer (AML versus ALL). The indirect method (shown in blue) performs better than the direct method (shown in
red). The difference is statistically significant (p = 0.0001 for the paired t-test on the underlying ranks).
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We have proposed a method for similarity search in gene
expression data and an evaluation method based on recall
at rank k. We have focused on the ability to detect simi-
larity despite known experimental biases, e.g., different
vehicles, different batches, or both different vehicles and
batches. The improvements in recall are not expected to
only help in overcoming such explained experimental
effects, but they are in fact representative of the larger set
of unknown environmental effects. It can thus be
assumed that the indirect similarity measure will be able
to overcome unknown changes in gene expression
experiments, and is therefore well suited for comparing
gene expression data from vastly different data sources.
Furthermore, we have shown that in a large, proprie-
tary dataset, this indirect method is able to overcome
experimental noise better and is able to recall a larger
number of drugs that are similar to the query drug.
More specifically, the indirect method was able to
increase the amount of known similar drugs recalled by
97.03% over the direct method in a real world drug dis-
covery program. These results have been validated on a
public dataset (Broad), for which the improvement in
recall was 49.44%. The difference in improvement is
representative of the fact that the Broad dataset is both
smaller and less complex, i.e., contains more replicates.
The benefit of the indirect method comes from the
information in the rest of the database, and therefore
the improvement is expected to increase as the size and
complexity of the database grows. While the improve-
ment relies on this added complexity in the database we
have shown that the indirect method still works on
smaller datasets. Specifically, we have demonstrated that
the indirect method improves the rank of recalling sam-
ples from the same class in three smaller, public datasets
and that this improvement is statistically significant.
These additional datasets also demonstrate the diverse
type of expression data that can benefit from the indir-
ect similarity method.
The indirect method increases the number of true
positives recalled at a particular threshold and this abil-
ity to recall 50-100% more compounds that are similar
(and therefore less false positives), gives researchers a
huge advantage in their analysis. In one scenario, using
the indirect method may decrease the amount of candi-
dates that might have to be followed up in an experi-
ment or drug discovery system, thereby saving time and
effort by not chasing false positives. This in turn allows
more confidence in the results generated by such a sys-
tem. More importantly, it also brings the community an
additional step closer to being able to pull together and
learn from the large amount of data that exists in the
public domain, which continues to grow every day.
However, it is important to acknowledge that there are
many potentially avenues for improvement and further
research for this problem. One of the advantages of the
indirect approach is that it can build upon any direct
similarity method. If better direct methods are devel-
oped in the future, then the indirect method can be
adapted to use such methods. The work presented in
this paper has dealt with the task of adapting to and
overcoming experimental bias in gene expression data,
specifically for the task of comparing two samples
directly. Other potential paths of future research could
include more complex comparisons, e.g., analyzing
groups of compounds together, as well as a more thor-
ough evaluation of selecting the optimal size of k for a
given dataset.
Methods
Vanda GEPedia Dataset Gene Expression Methods
The Vanda GEPedia Dataset was constructed from the
ARPE-19/HPV-16 and H4 cell lines which were
Table 8 Glucocorticoid Sensitivity/Resistance
Sample Class Indirect Direct
DT2004021428-738 S 10.1 12.6
DT2004021429-976 S 9.8 10.5
DT2004021430-1047 S 10.0 10.6
DT2004021431-1219 S 13.6 12.8
DT2004021432-1241 S 13.3 12.1
DT2004021433-1299 S 9.0 9.6
DT2004021434-1307 S 7.9 8.7
DT2004021435-1477 S 7.3 7.8
DT2004021436-1533 S 12.5 12.2
DT2004021437-1553 S 12.4 13.1
DT2004021438-1657 S 14.7 14.0
DT2004021439-1684 S 10.2 9.5
DT2004021440-1696 S 12.1 13.2
DT2004021441-329 R 11.0 12.1
DT2004021442-557 R 9.8 10.7
DT2004021443-685 R 16.8 15.7
DT2004021444-789 R 12.1 12.7
DT2004021446-865 R 20.3 19.2
DT2004021448-1466 R 13.3 13.9
DT2004021449-1652 R 13.3 14.8
DT2004021451-1755 R 11.9 12.7
DT2004021452-2078 R 11.9 13.3
DT2004021453-2200 R 16.5 15.7
DT2004021454-2209 R 14.1 14.5
DT2004021455-vu8978 R 12.0 13.3
DT2004021456-vu9023 R 10.2 11.8
DT2004021457-vu9573 R 10.5 10.7
DT2004021458-vu9728 R 12.0 13.3
DT2004021459-vu9951 R 13.9 14.6
The average rank of samples of the same class is listed for each sample. (S =
Glucocorticoid Sensitive; R = Glucocorticoid Resistant)
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Figure 7 Glucocorticoid Sensitivity/Resistance ROC. ROC curve showing the difference in sensitivity and specificity between the direct and
indirect method for the task of predicting sensitivity or resistance to glucocorticoids. The indirect method (shown in blue) improves upon the
direct method (shown in red). The difference is statistically significant (p = 0.0156 for the paired t-test on the underlying ranks).
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Figure 8 MEPs (megakaryocyte-erythrocyte progenitors) ROC. ROC curve showing the difference in sensitivity and specificity between the
direct and indirect method for the task of classifying cell types (megakaryocyte, erythrocyte, and their corresponding progenitors, i.e.,
megakaryocyte-erythrocyte progenitors). The indirect method (shown in blue) outperforms the direct method (shown in red). The difference is
statistically significant (p = 0.0035 for the paired t-test on the underlying ranks).
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Page 17 of 19obtained from ATCC (Manassas, Virginia), and propa-
gated in culture medium according to supplier’s specifi-
cation. Compounds were purchased from Sigma (St.
Louis, MO), with the exception of drugs developed by
Vanda Pharmaceuticals. Cells were aliquoted to 96-well
cell culture plate (~2 × 105 cells/well) and incubated for
24 hrs prior to providing fresh media with drug at a 10
uM.final concentration, or the drug vehicle (water,
DMSO, EtOH, or MEtOH). Cells were harvested 24 hrs
later and RNA was extracted using RNeasy 96 total
RNA protocol (Qiagen) as indicated by the manufac-
turer. Gene expression profiles were generated with
U133A2.0 microarrays following the manufacturer’s pro-
tocol (Affymetrix, Santa Clara, CA).
Significance and Specificity
A permutation test can be used to determine the signifi-
cance of a particular distribution of a set of instances in
an ordered list of all instances as was proposed by Lamb
et al. [8]. Such a permutation test works as follows. The
indirect similarity score is computed for the set of
t instances of interest, whether it be instances that
are replicates or belonging to the same group, in the
ordered list of all n instances, giving an average indirect
score I2R0. Then, for each of r trials, a random t
instances are selected from the full set of n instances
and the average indirect score for this set is calculated
and denoted I2Rr. The number of times, s,t h a tI2Rr
>I2R0 is counted and the frequency of such an event
(s/r) serves as a two-sided p-value.
Furthermore, the specificity of any results can also be
calculated in the same way as was done for the CMAP
approach. An outside set of signatures can be used, e.g.,
from the MSigDB as is the case with the CMAP, to
evaluate the uniqueness of the connections that are
detected.
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